Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD
Stopped The decision to terminate was completely related to efficacy and there were no safety concerns.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
Sponsor
Pfizer